Data for KEYTRUDA® (pembrolizumab) in a Range of Gastrointestinal Cancers to be Presented at 2016 Gastrointestinal Cancers Symposium

Dateline City: KENILWORTH, N.J. Seven Registration-Enabling Trials Evaluating KEYTRUDA in Patients with Gastrointestinal Cancers are Planned or Underway KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that new and updated findings investigating the use of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in multiple gastrointestinal cancers will be presented at this year’s Gastrointestinal (GI) Cancers Symposium in San Francisco, Jan. 21 – 23. Updates on pembrolizumab include data on advanced esophageal carcinoma and new preliminary Phase 2 safety data in gastric cancer. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558An Phan, 908-255-6325orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Source: Merck.com - Corporate News - Category: Pharmaceuticals Tags: Corporate News Latest News #Merck #MRK $MRK GI Cancers Symposium NYSE:MRK Source Type: news